--- title: FidoCure blog (10) description: Read the latest in veterinary oncology research and FidoCure® scientific and clinical updates. (10) --- [![FidoCure](https://blog.fidocure.com/hs-fs/hubfs/fidocure_logo.png?width=296&height=68&name=fidocure_logo.png "FidoCure")](https://www.fidocure.com/) - [Veterinarians](https://fidocure.com/for-veterinarians/) - [Portal Login](https://dvm.fidocure.com/) - [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet) - [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies) - [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars) - [Pet Parents](https://fidocure.com/pet-parents/) - [About Us](https://fidocure.com/about-us/) - [How it works](https://fidocure.com/how-it-works/) - [Find a Clinic](https://fidocure.com/find-a-clinic/) - [Contact Us](https://fidocure.com/contact-us/) # FidoCure Veterinary Team Blog ### Read the latest in veterinary oncology research and FidoCure scientific and clinical updates from our team of experts and advisors Select Category Case Studies Press Vet Webinars This is a search field with an auto-suggest feature attached. - There are no suggestions because the search field is empty. ![](https://blog.fidocure.com/hubfs/winston.jpg) ### [Insulinoma Case Study: Winston](https://blog.fidocure.com/fidocure-blog/metastic-insulinoma) #### With a combination approach that included FidoCure®, Winston survived two years following his initial diagnosis of metastatic insulinoma. [Read More](https://blog.fidocure.com/fidocure-blog/metastic-insulinoma) ![](https://blog.fidocure.com/hubfs/Imported_Blog_Media/shutterstock_124450252.jpg) ### [FidoCure® Precision Medicine Data Showcased at the American Association of Cancer Research (AACR)](https://blog.fidocure.com/fidocure-blog/new-comparative-oncology-research-showcasing-power-of-real-world-data-from-dogs-with-cancer) At the [AACR 2023 annual meeting](https://www.aacr.org/),  Dr. Lucas Rodrigues, Head of Veterinary Research at FidoCure®, presented the results of two innovative studies which demonstrated the power of real-world data from dogs with cancer to drive drug development strategies and inform human clinical trials. The first study, titled "High frequency of TP53 mutations in canine skin tumors recapitulates solar induced human lesions representing an important research model of spontaneous diseases," focused on the similarities between skin tumors in dogs and humans caused by sun exposure. The study found a high frequency of TP53 mutations in canine skin tumors, mirroring those seen in humans with solar-induced skin lesions. This validates the use of dogs as a valuable research model for spontaneous diseases. [Read More](https://blog.fidocure.com/fidocure-blog/new-comparative-oncology-research-showcasing-power-of-real-world-data-from-dogs-with-cancer) ![](https://blog.fidocure.com/hubfs/Imported_Blog_Media/thrive-logo.gif) ### [Thrive Pet Healthcare and FidoCure® Announce An Expansive Pet Precision Health Partnership](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/thrive-pet-healthcare-and-fidocure-r-announce-an-expansive-pet-precision-health-partnership/amp) *Strategic partnership leveraging FidoCure’s precision medicine platform advances joint vision for providing  personalized, accessible veterinary cancer care* [Read More](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/thrive-pet-healthcare-and-fidocure-r-announce-an-expansive-pet-precision-health-partnership/amp) ![](https://blog.fidocure.com/hubfs/Imported_Blog_Media/Chase-S.jpg) ### [Get to Know: Chase Schwalbach, Chief Product Officer, FidoCure](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/get-to-know/amp) ## Tell us about your background > I grew up on the Ohio/Kentucky border, from a relatively modest background. My mom worked 3 jobs to support me and my 2 siblings, and I... [Read More](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/get-to-know/amp) ![](https://blog.fidocure.com/hubfs/Imported_Blog_Media/shutterstock_1933410728.jpg) ### [World Veterinary Day Interview: Strengthening Veterinary Resilience](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/world-veterinary-day/amp) Resilience is defined as the capacity to recover quickly from difficulties and toughness-- there are both physical and psychological resilience. Both have been severely tested these last few years with the pandemic, the current war, national divisions, etc. and have really affected veterinarians in the world at large. [Read More](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/world-veterinary-day/amp) ![](https://blog.fidocure.com/hubfs/Imported_Blog_Media/Copy-of-Template_Rising-Women-in-Oncology_Instagram.jpg) ### [Rising Women in Veterinary Oncology](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/rising-women-in-veterinary-oncology/amp) ### An introduction from Chief Medical Officer, Dr. Gerry Post Veterinary medicine is changing. I remember one of my first days in veterinary school looking at the class pictures that were hung in the hallways. I remember seeing the first woman in one of these class photos and noting that she was still practicing. [Read More](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/rising-women-in-veterinary-oncology/amp) ![](https://blog.fidocure.com/hubfs/Imported_Blog_Media/shutterstock_116145664.jpg) ### [Medical Brief: PIK3CA and KRAS Mutations Predict for Response to Everolimus Therapy](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/medical-brief-august) PIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001 Morassa Mohseni, Ben Ho Park J Clin Invest. 2010;120(8):2655-2658. [https://doi.org/10.1172/JCI44026](https://doi.org/10.1172/JCI44026). [Read More](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/medical-brief-august) ![](https://blog.fidocure.com/hubfs/Imported_Blog_Media/shutterstock_1092921812.jpg) ### [Medical Brief: Treatment of Canine Cutaneous Epitheliotropic T-cell lymphoma with Olacitinib](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/medical-brief-treatment-of-canine-cutaneous-epitheliotropic-t-cell-lymphoma-with-oclacitinib-a-case-reportjeylan-aslan-michael-a-shipsto) ### Jeylan Aslan, Michael A. Shipstone and Louise M. Sullivan Vet Dermatol. 2021 May 25. doi: 10.1111/vde.12976 *This case study reviews the use of olacitinib to treat cutaneous epitheliotropic T-cell lymphoma (CETL).* [Read More](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/medical-brief-treatment-of-canine-cutaneous-epitheliotropic-t-cell-lymphoma-with-oclacitinib-a-case-reportjeylan-aslan-michael-a-shipsto) ![](https://blog.fidocure.com/hubfs/Imported_Blog_Media/Copy-of-FidoCure-Slides---5-.png) ### [Medical Brief:The Median Isn’t the Message](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/medical-brief-the-median-isnt-the-message/amp) ### Stephen J. Gould was one of the most influential authors of popular science. He was a paleontologist, evolutionary biologist and historian of science. The “Median Isn’t the Message” is an essay written by Stephen J. Gould in 1991 as part of his book *Bully for Brontosaurus: Reflections in Natural History.* The essay has been reprinted many times for many different audiences. In 2013 it was reprinted in the American Medical Association Journal of Ethics. I believe that Stephen J. Gould’s message is as relevant today as it was when he originally wrote it. I thought this essay so important and so well written, that it was required reading for every one of my residents over the past 20 years. [Read More](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/medical-brief-the-median-isnt-the-message/amp) ![](https://blog.fidocure.com/hubfs/Imported_Blog_Media/Dr_-Liz-Phluar-DVM--PhD--Diplomate-ACVS-Professor--Department-of-Veterinary-Clinical-Sciences--3-.png) ### [Win-Win -The Development of Novel Immunotherapies for Brain Tumors Using Pet Dogs](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/win-win-the-development-of-novel-immunotherapies-for-brain-tumors-using-pet-dogs) On Thursday **June 10th  at 3pm EST/12pm PST**, we were delighted to welcome **Dr. Liz Pluhar** to our webinar series. Dr. Pluhar is a full professor and small animal surgeon in the Department of Veterinary Clinical Sciences at the **University of Minnesota** and leads the **Canine Brain Tumor Clinical Trials Program.** [Read More](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/win-win-the-development-of-novel-immunotherapies-for-brain-tumors-using-pet-dogs) [8](https://blog.fidocure.com/fidocure-blog/page/8) [9](https://blog.fidocure.com/fidocure-blog/page/9) [10](https://blog.fidocure.com/fidocure-blog/page/10) [11](https://blog.fidocure.com/fidocure-blog/page/11) [12](https://blog.fidocure.com/fidocure-blog/page/12) ![fc_portal_logo_bw](https://blog.fidocure.com/hubfs/fc_portal_logo_bw.svg) - [How it Works](https://fidocure.com/how-it-works/) - [FAQ](https://fidocure.com/faq/) - [Contact Us](https://fidocurestg.wpengine.com/contact-us/) - [For Vets](https://fidocure.com/for-veterinarians/) - [About Us](https://fidocure.com/about-us/) - [Terms of Service](https://fidocure.com/terms-of-service/) - [Blog](https://blog.fidocure.com/fidocure-blog) - [Careers](https://fidocure.com/careers/) - [Privacy Policy](https://fidocure.com/privacy-policy/) - - - - **FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.  © Copyright 2018-2026 One Health Company, All rights reserved